- Report
- October 2026
- 227 Pages
Global
From €5405EUR$5,850USD£4,527GBP
- Report
- October 2026
- 170 Pages
Global
From €5405EUR$5,850USD£4,527GBP
- Report
- October 2026
- 274 Pages
Global
From €5405EUR$5,850USD£4,527GBP
- Report
- September 2026
- 120 Pages
Global
From €7382EUR$7,990USD£6,183GBP
- Report
- July 2026
- 143 Pages
Global
From €7382EUR$7,990USD£6,183GBP
- Report
- April 2026
- 180 Pages
Global
From €4389EUR$4,750USD£3,676GBP
- Report
- May 2026
- 150 Pages
Global
From €3465EUR$3,750USD£2,902GBP
- Report
- August 2026
- 130 Pages
Global
From €4389EUR$4,750USD£3,676GBP
- Report
- July 2026
- 130 Pages
Global
From €4389EUR$4,750USD£3,676GBP
- Report
- July 2026
- 130 Pages
Global
From €4389EUR$4,750USD£3,676GBP
- Report
- April 2026
- 165 Pages
Global
From €3649EUR$3,950USD£3,057GBP
- Report
- August 2026
- 183 Pages
Global
From €3649EUR$3,950USD£3,057GBP
- Report
- January 2026
- 107 Pages
Global
From €3500EUR$4,058USD£3,034GBP
- Report
- October 2026
- 308 Pages
Global
From €3500EUR$4,058USD£3,034GBP
- Report
- August 2026
- 328 Pages
Global
From €3234EUR$3,500USD£2,709GBP
- Report
- November 2025
- 139 Pages
Global
From €4296EUR$4,650USD£3,598GBP
- Report
- November 2025
- 135 Pages
Global
From €4481EUR$4,850USD£3,753GBP
- Report
- December 2025
- 150 Pages
United States
From €4481EUR$4,850USD£3,753GBP
- Report
- September 2025
- 180 Pages
Global
From €2772EUR$3,000USD£2,322GBP
- Report
- November 2024
- 600 Pages
Global
From €3049EUR$3,300USD£2,554GBP

The Neoantigen market is a subset of the Genomics market that focuses on the identification and development of neoantigens for use in cancer immunotherapy. Neoantigens are proteins that are produced by tumor cells and are recognized by the immune system as foreign, triggering an immune response. By targeting these neoantigens, cancer immunotherapy can be used to treat cancer. Companies in the Neoantigen market are focused on developing technologies to identify and develop neoantigens for use in cancer immunotherapy.
Companies in the Neoantigen market include Adaptive Biotechnologies, I-Mab, Neoantigen Therapeutics, NeoVax, and OncoImmune. Show Less Read more